FEATURE Chemicals & Pharmaceuticals
Growth in the UK and Irish
biopharmaceutical sector Digital Transformation at heart of introducing new effi ciencies
S
iemens commissioned study has identifi ed the UK and Irish biopharmaceutical sector’s key areas for priority inve stment
in digitalisation, with the challenges of time to market and making sense of large amounts of data running as a constant thread. The independent research engaged 31 key
players in the UK and Irish biopharmaceutical sector to discover key areas for business improvement. The study was conducted between late 2019 and early 2022, covering the period affected by the global pandemic. The key fi ndings indicate that digital
transformation in biopharmaceuticals is expected to pick up speed across the rest of the decade, with an increasing gulf likely to open up between leaders and laggards. Translating digitalisation into value for Pharma and Life Sciences manufacturing remains a key focus for many but the challenges of speed and effi ciency need to be addressed with urgency. The respondents also agreed that ‘Big Data’ and data analytics are crucial for driving quality and effi ciency, but it is vital to convert infi nite data into valuable insight through solutions like BioMAC from Siemens and the National Institute of Bioprocessing Research and Training (NIBRT) is helping organisations to translate data into meaningful and actionable information. The fi ndings also reveal that with much of pharmaceutical manufacturing still employing
16 September 2022 Irish Manufacturing
heavy use of paper-based records, the adoption of electronic batch records can help streamline process operations, improve regulatory compliance and reduce operational costs. Andrew Matthews, Head of Pharmaceuticals, Siemens, says: “The concept of a Digital Twin for pharma and life sciences is regrettably not widespread. At a recent ISPE event, it surprised me that only about a fi fth of the audience had heard of a Digital Twin, which means many have likely never heard of Industry 4.0 or Pharma 4.0! This short research underlines areas for consideration as identifi ed from the wider industry and is designed to spark further discussion.” Adrian Abbotts, Business Development Manager for Cell and Gene Therapies, Siemens, adds: “Working with our customers to understand their challenges, we have mapped out the sector’s business demands and aligned our solutions to mitigate them. Patients, products, pace of change and performance are areas of focus for our clients as they try to comprehend global infl uences such as changing demographics, new manufacturing techniques, tech transfer, supply chain complexity and outsourcing.” The majority of interviewees highlighted the critical importance of compressing the drug discovery process; in particular, using Industry 4.0 technology to accelerate the speed of new molecule development, such as through computational chemistry and data-driven
discovery. Connecting data ‘silos’ and enabling meaningful
data fl ows is driving moves towards greater standardisation in the industry. One bio- manufacturing technology company noted, “By introducing a new automation platform and further standardising our products, we are making it easy for our customers to integrate their systems into higher-level automation solutions.” Visibility of digital data fl ows in all aspects of biopharma – “from concept to clinic” – is also contributing to regulatory supervision, reducing the burden on biopharma companies, and at the same time increasing hard-pressed regulators’ and notifi ed bodies’ ability to scrutinise the industry. “It’s only a matter of time before we see remote inspections by the regulators becoming the norm,” said one respondent. The UK market, specifi cally, is estimated to surpass £12bn in 2022, with worldwide markets expecting an average growth rate of around 10 per cent per year. The UK and Ireland remain the number one destination for life sciences inward investment in Europe, ranks number two globally behind the US, and has also grown a thriving domestic industry with more than 5,600 companies producing some of the strongest research and development capability in Europe.
Siemens
www.siemens.com
www.irish-manufacturing.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42
